

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SR Medical
春雨医疗

SR MEDICAL TECHNOLOGY COMPANY LIMITED

春雨醫療科技有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 108)

PROFIT WARNING

This announcement is made by SR Medical Technology Company Limited (the “**Company**”) and its subsidiaries (collectively the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong).

The board (“**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on the preliminary review of the unaudited consolidated financial information of the Group for the six months ended 30 June 2026 and other information currently available to the Board, the Group expects to record a loss attributable to Shareholders ranging from approximately HK\$68.0 million to approximately HK\$73.0 million for the six months ended 30 June 2026, as compared to the profit attributable to Shareholders of approximately HK\$2.1 million in the corresponding period in 2025. The recognition of loss of the Group is mainly attributable to increase in (i) other operating costs of approximately HK\$75.2 million; (ii) finance costs of approximately HK\$29.3 million; and (iii) employee benefit expenses of approximately HK\$19.2 million, as partially offsetting by increase in revenue of approximately HK\$52.2 million in respect of (i) completion of acquisition of Beijing Chunyu Tianxia Software Co., Ltd.* (北京春雨天下軟件有限公司); and (ii) commencement of full operation of the Culver City project during the six months ended 30 June 2026 as compared to that of the corresponding period in 2025.

The information contained in this announcement is only a preliminary assessment made by the management of the Company based on the unaudited consolidated financial information of the Group and the information currently available to the Board, and such information has neither been audited nor reviewed by the auditors or audit committee of the Company. The Company is still in the process of preparing and finalising the results of the Group for the six months ended 30 June 2026, which are subject to further adjustments. Details of the Group’s financial performance will be contained in the interim results announcement of the Group for the six months ended 30 June 2026, which are expected to be published on 31 August 2026.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
SR Medical Technology Company Limited
Wei Chunxian
Chairman

Hong Kong, 26 August 2026

As at the date of this announcement, the executive directors of the Company are Mr. Wei Chunxian, Mr. Wei Laier, Mr. Sun Zhongmin, Mr. Chen Henan and Mr. Liu Bingyang; and the independent non-executive directors of the Company are Mr. Tung Woon Cheung Eric, Ms. To Tsz Wan Vivien and Mr. Huang Yining.

* *The English names of Chinese entities marked with “*” are translations of their Chinese names and are included for identification purpose only, and should not be regarded as their official English translation. In the event of any inconsistency, the Chinese name prevails.*